ACADIA Pharmaceuticals Director Makes a Significant Stock Sale

New insider activity at ACADIA Pharmaceuticals ( (ACAD) ) has taken place on June 5, 2025.

Director Laura Brege has recently sold 14,446 shares of ACADIA Pharmaceuticals stock, amounting to a total transaction value of $314,633.

Recent Updates on ACAD stock

In the last 24 hours, ACADIA Pharmaceuticals experienced significant developments, leading to notable changes in its stock price targets by various analysts. Deutsche Bank upgraded ACADIA to Buy from Hold, citing a favorable patent litigation outcome for Nuplazid, which extends its product lifecycle to 2038, providing greater revenue visibility post-2030. This legal victory against generics manufacturers has established a new valuation floor for the company. Additionally, the firm anticipates a positive setup for the upcoming Phase 3 data in Prader-Willi syndrome. Other analysts, including Morgan Stanley, BMO Capital, and Mizuho, also raised their price targets, reflecting increased confidence in ACADIA’s revenue growth and strategic advancements. The company’s recent Q1 earnings call highlighted impressive revenue growth, particularly in key products like DAYBUE and NUPLAZID, and emphasized its commitment to pipeline progress and European expansion, despite facing challenges such as increased R&D expenses and sequential sales decline.

Spark’s Take on ACAD Stock

According to Spark, TipRanks’ AI Analyst, ACAD is a Outperform.

ACADIA Pharmaceuticals’ strong financial performance and positive earnings call are key strengths, driving a favorable overall score. Technical indicators show bullish momentum, though caution is advised due to overbought conditions. The company’s valuation is reasonable, and recent corporate events further bolster its strategic position.

To see Spark’s full report on ACAD stock, click here.

More about ACADIA Pharmaceuticals

YTD Price Performance: 16.67%

Average Trading Volume: 2,077,432

Technical Sentiment Signal: Buy

Current Market Cap: $3.68B